Evidence map›Paper›PMID 25728721›Full record

ReviewAmerican heart journal2015

A reappraisal of loop diuretic choice in heart failure patients.

Jonathan Buggey, Robert J Mentz, Bertram Pitt, Eric L Eisenstein, Kevin J Anstrom, Eric J Velazquez, Christopher M O'Connor

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American heart journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Diuretic Use in Heart Failure.Reviews in cardiovascular medicine · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jonathan BuggeyDuke University Medical Center, Durham, NC. Electronic address: jonathan.buggey@duke.edu.
Robert J MentzDuke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.
Bertram PittUniversity of Michigan Health System, Ann Arbor, MI.
Eric L EisensteinDuke Clinical Research Institute, Durham, NC.
Kevin J AnstromDuke Clinical Research Institute, Durham, NC.
Eric J VelazquezDuke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.
Christopher M O'ConnorDuke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.
Clinical Research Institute · USDuke Medical Center · USMichigan Medicine · US

Funding

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5M
NIGMS NIH HHS T32 GM086330NIGMS NIH HHS T32GM086330
6 · The paper itself

Abstract

The health and economic burden of heart failure is significant and continues to grow each year. Loop diuretics are an integral part of symptom management in heart failure. Furosemide is used disproportionately compared with other loop diuretics, and there is currently no guidance for physicians regarding which agent to choose. However, there exist pharmacologic differences as well as other mechanistic differences that appear to favor torsemide use over furosemide. Compared with furosemide, torsemide improves surrogate markers of heart failure severity such as left ventricular function, plasma brain natriuretic peptide levels, and New York Heart Association functional class and may also reduce hospitalizations, readmissions, and mortality. Data suggest that these benefits could be mediated through torsemide's ability to positively affect the renin-angiotensin-aldosterone system. Specifically, torsemide has been shown to inhibit aldosterone secretion, synthesis, and receptor binding in vitro, as well as decrease transcardiac extraction of aldosterone, myocardial collagen production, and cardiac fibrosis in patients with heart failure. We identified pertinent literature using keyword MEDLINE searches and cross-referencing prior bibliographies. We summarize the available data suggesting potential benefits with torsemide over furosemide, and call attention to the need for a reappraisal of diuretic use in heart failure patients and also for a well-powered, randomized control trial assessing torsemide versus furosemide use.

Indexed as

Practice Patterns, Physicians'Choice BehaviorFibrosisFurosemideHeartHeart FailureHumansMyocardiumRenin-Angiotensin SystemSodium Potassium Chloride Symporter InhibitorsSulfonamidesTorsemideUp-RegulationVentricular Dysfunction, LeftFurosemideSodium Potassium Chloride Symporter InhibitorsSulfonamidesTorsemide

Identifiers

PMID25728721
PMCPMC4346710
OpenAlexW2040618276

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.